Journal article

A therapeutic Porphyromonas gingivalis gingipain vaccine induces neutralising IgG1 antibodies that protect against experimental periodontitis

Neil M O'Brien-Simpson, James A Holden, Jason C Lenzo, Yan Tan, Gail C Brammar, Katrina A Walsh, William Singleton, Rebecca KH Orth, Nada Slakeski, Keith J Cross, Ivan B Darby, Dorit Becher, Tony Rowe, Adriana Baz Morelli, Andrew Hammet, Andrew Nash, Anna Brown, Bing Ma, Didier Vingadassalom, Jacqueline McCluskey Show all



Porphyromonas gingivalis infected mice with an established P. gingivalis-specific inflammatory immune response were protected from developing alveolar bone resorption by therapeutic vaccination with a chimera (KAS2-A1) immunogen targeting the major virulence factors of the bacterium, the gingipain proteinases. Protection was characterised by an antigen-specific IgG1 isotype antibody and Th2 cell response. Adoptive transfer of KAS2-A1-specific IgG1 or IgG2 expressing B cells confirmed that IgG1-mediated protection. Furthermore, parenteral or intraoral administration of KAS2-A1-specific polyclonal antibodies protected against the development of P. gingivalis-induced bone resorption. The KAS2-A..

View full abstract


Funding Acknowledgements

The work was supported by the Australian Government, Department of Industry, Innovation and Science, Sanofi Pasteur and CSL. Professor David Tarlington is acknowledged for advice on the B cell adoptive transfer experiments. Katrina Laughton, Natasha Swan and Stephen Cleal are acknowledged for technical assistance.